Can patients realistically inject themselves weekly for 50 years?
Retatrutide works by mimicking three hormones (GLP-1, GIP, glucagon) to reduce appetite, slow digestion, and increase metabolic burn—a mechanism more comprehensive than existing obesity drugs. Trial data shows 30.3% weight loss at maximum doses with improved cardiometabolic health, but side effects include nausea (42.4%), constipation, and an 11.3% dropout rate at highest doses.
- 30.3% weight loss at maximum dose over two years in severe obesity cases
- Triple hormone agonist: mimics GLP-1, GIP, and glucagon
- 5,800+ trial participants; 11.3% dropout rate at highest doses
- Nausea in 42.4% of patients on maximum dose; constipation in ~26%
Retatrutide, a triple-action hormone agonist in clinical trials, achieves 30% weight loss in severe obesity cases over two years—matching bariatric surgery results. Experts urge caution about long-term safety and continuous use requirements.
A new experimental drug has achieved weight loss results that rival bariatric surgery, losing an average of 30 percent of body weight in patients with severe obesity over two years. The medication, called retatrutida, works through a mechanism more sophisticated than existing obesity treatments—it mimics three separate hormones rather than one or two, allowing it to suppress appetite, slow stomach emptying, and crucially, increase the body's calorie burn at rest.
The drug's mechanism represents a meaningful advance in how these medications work. Existing treatments like Ozempic and Wegoby rely on semaglutida, a molecule that mimics GLP-1, a hormone that controls blood sugar. Mounjaro uses tirzepatida, which acts on both GLP-1 and another hormone called GIP. Retatrutida goes further by also activating glucagon, which accelerates metabolic expenditure. This triple action appears to overcome a fundamental problem with dieting: when people restrict calories, the body enters a conservation mode, reducing energy expenditure. By targeting glucagon, retatrutida appears to counteract this metabolic slowdown, burning more calories even at rest.
The trial results are striking. At the lowest tested dose of 4 milligrams, patients achieved 19 percent weight loss over twenty months. The maximum tolerated dose of 12 milligrams produced 28.3 percent loss in the same timeframe, climbing to 30.3 percent by the two-year mark. The drug also showed improvements in cardiometabolic health measures. Ania Jastreboff, a Yale endocrinologist and lead investigator on the trial, described observing clinically significant weight reduction in nearly all participants who received the highest dose, calling it a potential tool of major impact for treating obesity and transforming patients' health trajectories.
Yet medical experts are urging caution. Amador Ruiz, a bariatric surgeon at Hospital Donostia in Spain's Basque Country, acknowledges the data is impressive and comparable to surgical outcomes, but raises a critical question: patients undergoing bariatric surgery are typically between 30 and 45 years old, with a life expectancy around 80 in the Basque region. These medications require continuous weekly injections to maintain their effects. Can patients realistically inject themselves weekly for 50 years? Ruiz also notes that while the two-year safety profile is known, the long-term effects remain unknown.
Irene Bretón, coordinator of the obesity area at Spain's Society of Endocrinology and Nutrition, echoes this concern. She describes retatrutida as an extremely potent drug—comparable to a blood pressure medication that cuts pressure in half—and warns that while the expanding arsenal of obesity treatments is welcome, careful consideration is essential. The side effects observed in over 5,800 trial participants since 2023 mirror those of related drugs: nausea affected 28.6 percent of those on the minimum dose and 42.4 percent on the maximum dose, constipation occurred in roughly a quarter of participants, and upper respiratory infections appeared in around 13 to 14 percent. More concerning is the 11.3 percent dropout rate among those receiving the highest doses, a figure Ruiz suggests signals that real-world abandonment rates will likely exceed the 50 percent seen with current obesity medications.
Retatrutida is administered as a weekly injection to adults with obesity or overweight and at least one weight-related health condition, excluding those with diabetes. The drug is designed to be taken indefinitely to maintain its effects. As these medications move from clinical trials toward potential approval and widespread use, the central tension remains unresolved: the impressive short-term results must be weighed against the unknown consequences of decades of continuous use and the practical question of whether patients will sustain treatment over the long term.
Notable Quotes
The data are very good, fantastic. And they are indeed similar to what is achieved with surgery.— Amador Ruiz, bariatric surgeon, Hospital Donostia
It is like a blood pressure medication that cuts pressure in half—we must be very careful because this is an extremely potent drug.— Irene Bretón, coordinator of obesity area, Spanish Society of Endocrinology and Nutrition
The Hearth Conversation Another angle on the story
What makes retatrutida fundamentally different from Ozempic or Mounjaro?
It's the third hormone. The older drugs work on one or two hormonal pathways. Retatrutida activates three—it's like having three different tools instead of two. The crucial one is glucagon, which doesn't just control blood sugar; it makes your body burn more calories even when you're sitting still.
Why does that matter so much?
Because dieting is a losing battle against your own biology. When you eat less, your body fights back by conserving energy. It's like your metabolism goes into airplane mode. Retatrutida seems to override that response.
The results sound almost too good. Why are doctors hesitant?
Because nobody knows what happens in year ten, or year thirty. These are weekly injections you'd take for the rest of your life. We have two years of data. We don't have fifty.
What about the side effects?
Nausea, constipation, infections—they're manageable for most people. But one in nine people on the highest dose quit the trial. That's a warning sign. If that happens in the real world, the drug's promise evaporates.
So this isn't a miracle cure?
It's a powerful tool with real results. But it demands commitment, and we're still writing the story of what that commitment costs over a lifetime.